The general model that dominant diseases are caused by mutations that result in a gain or change in function of the corresponding protein was challenged by the discovery that the myotonic dystrophy type 1 mutation is a CTG expansion located in the 3Ј untranslated portion of a kinase gene. The subsequent discovery that a similar transcribed but untranslated CCTG expansion in an intron causes the same multisystemic features in myotonic dystrophy type 2 (DM2), along with other developments in the DM1 field, demonstrate a mechanism in which these expansion mutations cause disease through a gain of function mechanism triggered by the accumulation of transcripts containing CUG or CCUG repeat expansions. A similar RNA gain of function mechanism has also been implicated in fragile X tremor ataxia syndrome (FXTAS) and may play a role in pathogenesis of other non-coding repeat expansion diseases, including spinocerebellar ataxia type 8 (SCA8), SCA10, SCA12 and Huntington disease-like 2.
Fragile X mental retardation (FMR) and Friedreich's ataxia (FA), both caused by non-coding triplet repeat expansions, were among the first trinucleotide repeat disorders described [1, 2] . Consistent with the paradigm that recessive disorders are caused by loss of function mechanisms, these noncoding expansions prevent normal protein expression [1, 2] . The discovery that dominant diseases such as Huntington disease and several spinocerebellar ataxias are caused by CAG expansions that are translated into polyglutamine tracks affecting their corresponding proteins, follows the paradigm that dominant diseases are caused by a gain or change of function of the corresponding mutant protein [3] . This straightforward and relatively simple model was complicated by the discovery that dominantly inherited myotonic dystrophy type 1 (DM1) is caused by an untranslated CTG expansion in the 3Ј noncoding region of the DMPK gene [4] [5] [6] . The discovery that a second form of myotonic dystrophy, myotonic dystrophy type 2 (DM2), is caused by a noncoding CCTG repeat expansion, provided strong support for a gain of function mechanism in which microsatellite expansions can be pathogenic at the RNA level [7] . There is now a growing body of evidence that repeat expansions expressed at the RNA level, but not the protein level, cause fragile-X tremor ataxia syndrome (FXTAS) [8, 9] and possibly other disorders including spinocerebellar ataxia type 8 (SCA8), SCA10, SCA12, and Huntington's disease like 2 (HDL2) [10] [11] [12] [13] .
Myotonic Dystrophy Type 1: Identification of the First Dominant Non-Coding Expansion Disorder
In 1992, a CTG expansion in the 3Ј untranslated region of the dystrophia myotonica-protein kinase gene (DMPK) was shown to cause myotonic dystrophy (DM), the most common form of muscular dystrophy in adults [4, 5] . For the following seven years this was the only example of an untranslated trinucleotide expansion causing a dominant disease; the mechanism underlying the pathogenesis of this unusual mutation remained elusive because the dominant inheritance pattern was difficult to reconcile with the location of the expansion in a portion of the kinase gene that would not affect the protein sequence [14] . Several models to explain how the CTG expansion might cause the unusual constellation of features associated with DM1 included: (i) haploinsufficiency of the DMPK protein; (ii) altered expression of neighboring genes, including the homeodomain gene SIX5; and (iii) pathogenic effects of the CUG expansion in RNA, which accumulates as ribonuclear foci in affected tissue and causes downstream disruptions in alternative splicing [10, 14] . The mouse models created to elucidate the pathogenesis for DM1 each developed aspects of the multisystemic phenotype: an RNA gain of function model that Mankodi et al. developed, in which a CTG expansion of ϳ250 repeats was expressed at the 3Ј UTR of the unrelated human skeletal actin gene causes myotonia and myopathic features [15] ; a homozygous Dmpk knockout develops cardiac abnormalities [16, 17] ; and a knockout model of the neighboring Six5 gene causes cataracts, though not the specific posterior iridescent cataracts seen in patients [18, 19] . Taken together, each of these transgenic mice was thought to provide support for the concept that DM1 is a regional gene disorder with each of the proposed mechanisms contributing to disease pathogenesis [14] . While the additive model was appealing, an inconsistency was that the genetic locus for a second form of myotonic dystrophy (DM2) had been mapped to a different chromosome. The lack of synteny between the DM2 region on chromosome 3 with the DM1 locus on chromosome 19 made a mechanism involving the additive effects of multiple dysregulated genes at the DM1 locus seem unlikely [14, 20] .
Discovery of DM2 Sheds Light on the Pathogenicity of Non-Coding Repeats
After genetic testing became available for DM1 in 1992, some individuals with the rare and complex clinical presentation of DM were identified who did not have the CTG expansion [21, 22] . As in DM1, these patients had myotonia, characteristic histological abnormalities in skeletal muscle, posterior iridescent cataracts, severe cardiac arrhythmias, hypotestosteronism and oligospermia, and insulin insensitivity [23] . We identified and subsequently used a large family with similar multisystemic clinical features to map the second locus, designated myotonic dystrophy type 2 (DM2), to chromosome 3q21 [20, 24] .
In 2001, Liquori et al. demonstrated that DM2 is caused by a CCTG repeat expansion in intron 1 of the zinc finger protein 9 (ZNF9) gene. Similar to DM1, the DM2 repeat tract is transcribed but not translated [7] and CCUG-containing ribonuclear inclusions accumulate in DM2 skeletal muscle [7] . Although DM2 patients often have a milder disease course than individuals with DM1, the DM2 CCTG repeat expansions are generally much larger than those for DM1, ranging in size from ϳ75 to 11,000 repeats with a mean of ϳ5,000 repeats [25] . Because somatic instability causes a broad range of DM2 allele sizes in individual patients, which are evident as smears by Southern analysis -rare individuals with the smallest repeat expansions (75-100 CCTGs) also have other larger expansion sizes, therefore preventing a clear definition of the smallest pathogenic repeat size [7] .
The function of ZNF9 and surrounding genes at the DM2 locus (KIAA1160, Rab11B, glycoprotein IX, FLJ11631, and FLJ12057) bear no obvious similarity to the genes found at the DM1 locus (SIX5 and DMWD) [14, 26, 27] . Although the additive model of DM1 proposed that RNA containing the CUG expansion caused myotonia and muscular dystrophy, it was also thought that the haploinsufficiency of DMPK and surrounding genes such as SIX5 contributed to other features of the disease, including cardiac conduction defects and cataracts [25] . The isolation of the DM2 mutation and the clinical and molecular parallels between DM1 and DM2 now provide strong support for the model in which the broad constellation of clinical features associated with DM1 and DM2 is caused by a gain of function RNA mechanism ( fig. 1 ) [7, 28] .
Evidence Supporting an RNA Gain of Function Mechanism in the Myotonic Dystrophies
The following lines of evidence support an RNA gain of function model for the myotonic dystrophies: a) the DM1 expansion in the 3ЈUTR of the DMPK mRNA has the ability to inhibit myoblast differentiation in cell culture and myogenesis in murine models [29, 30] ; b) repeat tracts of more than 250 CTGs cause myotonia and myopathy when expressed at the RNA level in the 3Ј UTR of the DMPK or human skeletal muscle actin (HSA) gene in transgenic animals [15, 31] ; c) specific RNA binding proteins, CUG-BP and three forms of muscleblind (MBNL, MBLL, and MBXL), have altered regulation or localization in cell culture models of both . The RNA transcripts containing expanded CUG repeat tracks cause an increase in CUG-BP protein, however, the mechanism for this increase is currently unknown [35, 36] . In contrast, expanded DM1 and DM2 transcripts are thought to Fig. 1 . RNA model of DM pathogenesis. Clinical and molecular parallels between DM1 and DM2 simplify previous models of DM pathogenesis and demonstrate that the multisystemic features shared by DM1 and DM2 are caused by an RNA mechanism mediated by CUG-and CCUG-containing transcripts. CUG-and CCUG-containing transcripts accumulate as ribonuclear foci. The subsequent dysregulation of RNA binding proteins, including CUG-BP and the muscleblind protein MBNL1, leads to disruptions in the regulation of normal alternative splicing, leading to the multisystemic features common to DM1 and DM2 ([86] , reprinted with permission from Elsevier©). 
